China has approved Beyfortus, a long-acting antibody from AstraZeneca and Sanofi, to help prevent respiratory syncytial virus (RSV) infections in babies and newborns.

AstraZeneca and Sanofi's RSV infant vaccine, Beyfortus, has received approval in China. It has already been greenlit in the United States and European Union. The vaccine, intended for the prevention of RSV in neonates and infants for their first RSV season, has been approved by China's National Medical Products Administration based on three late-stage clinical studies and an extensive local clinical development program.

January 02, 2024
15 Articles